These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 15447674)

  • 1. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
    Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
    J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD; Johnson GV
    Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.
    Ribeiro M; Silva AC; Rodrigues J; Naia L; Rego AC
    Toxicol Sci; 2013 Dec; 136(2):487-99. PubMed ID: 24008831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
    Wang X; Sarkar A; Cicchetti F; Yu M; Zhu A; Jokivarsi K; Saint-Pierre M; Brownell AL
    J Neurol Sci; 2005 Apr; 231(1-2):57-66. PubMed ID: 15792822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
    Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
    Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
    Pinto JT; Van Raamsdonk JM; Leavitt BR; Hayden MR; Jeitner TM; Thaler HT; Krasnikov BF; Cooper AJ
    J Neurochem; 2005 Aug; 94(4):1087-101. PubMed ID: 15992377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Vecsei L; Klivenyi P
    Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.
    Li X; Valencia A; Sapp E; Masso N; Alexander J; Reeves P; Kegel KB; Aronin N; Difiglia M
    J Neurosci; 2010 Mar; 30(13):4552-61. PubMed ID: 20357106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
    Karpuj MV; Becher MW; Springer JE; Chabas D; Youssef S; Pedotti R; Mitchell D; Steinman L
    Nat Med; 2002 Feb; 8(2):143-9. PubMed ID: 11821898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
    Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
    Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
    Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
    J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
    Wang N; Lu XH; Sandoval SV; Yang XW
    J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Wu CH
    Clin Interv Aging; 2015; 10():1825-37. PubMed ID: 26609226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.